research_clinicaltrials

A listing of the open clinical trials at the MAC

Ataxia Trial of BHV-4157

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

Summary

  • Study director: Michael Geschwind, MD, PhD
  • Sponsor: Biohaven Pharmaceutical Holding Company Ltd.
  • Recruiting?: Yes
  • Official study title: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Parkinson's Disease Trial of iPad-Based Cognitive Exercise

The primary goal of this study is to carry out a randomized clinical trial assessing the efficacy of two different versions of iPad-based EVO game-play (EVO-multitask and EVO-visual search) on cognition in PD patients

Summary

  • Study director: Joel Kramer, PsyD
  • Recruiting?: Yes
  • Official study title: Study of Project: EVO Exercise in Parkinson’s Disease
  • Fox Trial Finder identifier: 4918

Alzheimer's Disease Trial with Crenezumab - Phase 3

The purpose of this study is to evaluate the efficacy and safety of crenezumab in patients with prodromal to mild Alzheimer’s disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: F. Hoffmann-La Roche Ltd.
  • Recruiting?: Yes
  • Official study title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease

Progressive Supranuclear Palsy Trial of ABBV-8E12

The purpose of this study is to evaluate the efficacy and safety of ABBV-8E12 in patients with progressive supranuclear palsy.

Summary

  • Study director: Richard Tsai, MD
  • Sponsor: AbbVie
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02985879

Alzheimer’s Disease Trial with Aducanumab

The primary purpose of this study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Biogen
  • Recruiting?: Yes
  • Official study title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Progressive Supranuclear Palsy Trial with C2N-8E12

The primary purpose of this study is to determine the safety, tolerability, and maximally tolerated dosage of C2N-8E12, and anti-tau monoclonal antibody. C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to remove tau protein. The tau protein is believed to build up to abnormally high levels in the brains of individuals with PSP. This abnormal accumulation is associated with clinical progression of the disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: C2N Diagnostics
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Trial with BMS-986168

The primary purpose of this study is to see how safe and well tolerated the study drug BMS-986168 is at different drug amounts in patients with PSP and to measure the amount of study drug in subject’s blood and cerebrospinal fluid (CSF) after taking the drug.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Bristol-Myers Squibb Company (BMS)
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy Trial of Oral Salsalate

Salsalate has been marketed for decades in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorders, but this is the first time salsalate will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of oral salsalate in people with PSP.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02422485

Progressive Supranuclear Palsy Trial of Plasma Transfusions

Young healthy male donor plasma is commonly used to correct clotting deficiencies, but this is the first time it will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of donor plasma transfusions in patients with PSP.

Summary

  • Study director: Richard Tsai, MD, MBA
  • Funder: Tau Consortium
  • Recruiting?: No
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy

Frontotemporal Dementia with Granulin Mutation Trial of a Histone Deacetylase Inhibitor

The aim of this trial is to evaluate the safety and tolerability of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin mutation and to see if it causes a change in plasma concentrations of progranulin.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: FORUM Pharmaceuticals
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
Syndicate content